Vascular smooth muscle cell-selective peroxisome proliferator-activated receptor-y deletion leads to hypotension

Circulation

Volumn 119, Issue 16, 2009, Pages 2161-2169

  Chang, Lin ^a   Villacorta, Luis ^a   Zhang, Jifeng ^a   Garcia Barrio, Minerva T ^b   Yang, Kun ^a   Hamblin, Milton ^a   Whitesall, Steven E ^c   D'Alecy, Louis G ^c   Chen, Y Eugene ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b MOREHOUSE SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Diabetes mellitus; Hypertension; Lipids; Obesity

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; NORADRENALIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; 2,4 THIAZOLIDINEDIONE DERIVATIVE; VASOCONSTRICTOR AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA CONSTRICTION; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME REPRESSION; FEMALE; GENE DELETION; HYPOTENSION; IN VITRO STUDY; KNOCKOUT MOUSE; MODULATION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REST; SMOOTH MUSCLE FIBER; TRANSCRIPTION REGULATION; VASCULAR SMOOTH MUSCLE; VASODILATATION; ANIMAL; AORTA; BLOOD PRESSURE; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; DRUG POTENTIATION; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; MOUSE MUTANT; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PHYSIOLOGY; PROMOTER REGION; SIGNAL TRANSDUCTION;

ANIMALS; AORTA; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; GENE EXPRESSION REGULATION; HYPOTENSION; MICE; MICE, KNOCKOUT; MUSCLE, SMOOTH, VASCULAR; NOREPINEPHRINE; PPAR GAMMA; PROMOTER REGIONS, GENETIC; RECEPTORS, ADRENERGIC, BETA-2; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES; TRANSCRIPTION, GENETIC; VASOCONSTRICTOR AGENTS; VASODILATION;

EID: 66549127391     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.108.815803     Document Type: Article

References (34)

1. Fonseca VA, Kulkarni KD. Management of type 2 diabetes: oral agents, insulin, and injectables. J Am Diet Assoc. 2008;108:S29-S33.
2. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med. 2004;351: 1106-1118.
3. Duan SZ, Usher MG, Mortensen RM. Peroxisome proliferator-activated receptor-gamma-mediated effects in the vasculature. Circ Res. 2008;102: 283-294.
4. Raji A, Seely EW, Bekins SA, Williams GH, Simonson DC. Rosigli- tazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care. 2003;26:172-178.
5. Ogihara T, Rakugi H, Ikegami H, Mikami H, Masuo K. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertens. 1995;8:316-320.
6. Ghazzi MN, Perez JE, Antonucci TK, Driscoll JH, Huang SM, Faja BW, Whitcomb RW. Cardiac and glycemic benefits of troglitazone treatment in NIDDM: the Troglitazone Study Group. Diabetes. 1997;46:433-439.
7. Barroso I, Gurnell M, Crowley VE, Agostini M, Schwabe JW, Soos MA, Maslen GL, Williams TD, Lewis H, Schafer AJ, Chatterjee VK, O'Rahilly S. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature. 1999;402:880-883.
8. Campia U, Matuskey LA, Panza JA. Peroxisome proliferator-activated receptor-gamma activation with pioglitazone improves endothelium- dependent dilation in nondiabetic patients with major cardiovascular risk factors. Circulation. 2006;113:867-875.
9. Sorrentino SA, Bahlmann FH, Besler C, Muller M, Schulz S, Kirchhoff N, Doerries C, Horvath T, Limbourg A, Limbourg F, Fliser D, Haller H, Drexler H, Landmesser U. Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes mellitus: restoration by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Circulation. 2007;116:163-173.
10. Duan SZ, Ivashchenko CY, Whitesall SE, D'Alecy LG, Duquaine DC, Brosius FC, 3rd, Gonzalez FJ, Vinson C, Pierre MA, Milstone DS, Mortensen RM. Hypotension, lipodystrophy, and insulin resistance in generalized PPARgamma-deficient mice rescued from embryonic lethality. J Clin Invest. 2007;117:812-822.
11. Nicol CJ, Adachi M, Akiyama TE, Gonzalez FJ. PPARgamma in endo- thelial cells influences high fat diet-induced hypertension. Am J Hypertens. 2005;18:549-556.
12. Zhang J, Zhong W, Cui T, Yang M, Hu X, Xu K, Xie C, Xue C, Gibbons GH, Liu C, Li L, Chen YE. Generation of an adult smooth muscle cell-targeted Cre recombinase mouse model. Arterioscler Thromb Vasc Biol. 2006;26:e23-e24.
13. He W, Barak Y, Hevener A, Olson P, Liao D, Le J, Nelson M, Ong E, Olefsky JM, Evans RM. Adipose-specific peroxisome proliferator-ac- tivated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle. Proc Natl Acad Sci U S A. 2003;100: 15712-15717.
14. Hansmann G, de Jesus Perez VA, Alastalo TP, Alvira CM, Guignabert C, Bekker JM, Schellong S, Urashima T, Wang L, Morrell NW, Rabinovitch M. An antiproliferative BMP-2/PPARgamma/apoE axis in human and murine SMCs and its role in pulmonary hypertension. J Clin Invest. 2008;118:1846-1857.
15. Wang N, Yang G, Jia Z, Zhang H, Aoyagi T, Soodvilai S, Symons JD, Schnermann JB, Gonzalez FJ, Litwin SE, Yang T. Vascular PPARgamma controls circadian variation in blood pressure and heart rate through Bmal1. Cell Metab. 2008;8:482-491.
16. Duan SZ, Ivashchenko CY, Usher MG, Mortensen RM. PPAR-gamma in the cardiovascular system. PPAR Res. 2008;2008:745804.
17. Hamblin M, Chang L, Fan Y, Zhang J, Chen YE. PPARs and the cardiovascular system. Antioxid Redox Signal. 2009;11:1415-1452.
18. Villacorta L, Schopfer FJ, Zhang J, Freeman BA, Chen YE. PPARgamma and its ligands: therapeutic implications in cardiovascular disease. Clin Sci (Lond). 2009;116:205-218.
19. Xu R, Ho YS, Ritchie RP, Li L. Human SM22 alpha BAC encompasses regulatory sequences for expression in vascular and visceral smooth muscles at fetal and adult stages. Am J Physiol Heart Circ Physiol. 2003;284:H1398-H1407.
20. Iaccarino G, Cipolletta E, Fiorillo A, Annecchiarico M, Ciccarelli M, Cimini V, Koch WJ, Trimarco B. Beta(2)-adrenergic receptor gene delivery to the endothelium corrects impaired adrenergic vasorelaxation in hypertension. Circulation. 2002;106:349-355.
21. Beyer AM, Baumbach GL, Halabi CM, Modrick ML, Lynch CM, Gerhold TD, Ghoneim SM, de Lange WJ, Keen HL, Tsai YS, Maeda N, Sigmund CD, Faraci FM. Interference with PPARgamma signaling causes cerebral vascular dysfunction, hypertrophy, and remodeling. Hypertension. 2008;51:867-871.
22. Halabi CM, Beyer AM, de Lange WJ, Keen HL, Baumbach GL, Faraci FM, Sigmund CD. Interference with PPAR gamma function in smooth muscle causes vascular dysfunction and hypertension. Cell Metab. 2008; 7:215-226.
23. Beyer AM, de Lange WJ, Halabi CM, Modrick ML, Keen HL, Faraci FM, Sigmund CD. Endothelium-specific interference with peroxisome proliferator activated receptor gamma causes cerebral vascular dysfunction in response to a high-fat diet. Circ Res. 2008;103:654-661.
24. Diep QN, Schiffrin EL. Increased expression of peroxisome proliferator- activated receptor-alpha and -gamma in blood vessels of spontaneously hypertensive rats. Hypertension. 2001;38:249-254.
25. Wakino S, Hayashi K, Kanda T, Tatematsu S, Homma K, Yoshioka K, Takamatsu I, Saruta T. Peroxisome proliferator-activated receptor gamma ligands inhibit Rho/Rho kinase pathway by inducing protein tyrosine phosphatase SHP-2. Circ Res. 2004;95:e45-e55.
26. Atkins KB, Northcott CA, Watts SW, Brosius FC. Effects of PPAR-gamma ligands on vascular smooth muscle marker expression in hypertensive and normal arteries. Am J Physiol Heart Circ Physiol. 2005;288:H235-H243.
27. Benkirane K, Viel EC, Amiri F, Schiffrin EL. Peroxisome proliferator- activated receptor gamma regulates angiotensin II-stimulated phosphati- dylinositol 3-kinase and mitogen-activated protein kinase in blood vessels in vivo. Hypertension. 2006;47:102-108.
28. Diep QN, El Mabrouk M, Cohn JS, Endemann D, Amiri F, Virdis A, Neves MF, Schiffrin EL. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma. Circulation. 2002; 105:2296-2302.
29. RyanMJ, DidionSP, MathurS, Faraci FM, Sigmund CD. PPAR(gamma) agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice. Hypertension. 2004;43: 661-666.
30. Hansmann G, Wagner RA, Schellong S, Perez VA, Urashima T, Wang L, Sheikh AY, Suen RS, Stewart DJ, Rabinovitch M. Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-gamma activation. Circulation. 2007;115: 1275-1284.
31. Ameshima S, Golpon H, Cool CD, Chan D, Vandivier RW, Gardai SJ, Wick M, Nemenoff RA, Geraci MW, Voelkel NF. Peroxisome proliferator-activated receptor gamma (PPARgamma) expression is decreased in pulmonary hypertension and affects endothelial cell growth. CircRes. 2003;92:1162-1169.
32. Long X, Miano JM. Remote control of gene expression. J Biol Chem. 2007;282:15941-15945.
33. Curtis AM, Cheng Y, Kapoor S, Reilly D, Price TS, FitzGerald GA. Circadian variation of blood pressure and the vascular response to asynchronous stress. Proc Natl Acad Sci USA. 2007;104:3450-3455.
34. Kim SM, Huang Y, Qin Y, Mizel D, Schnermann J, Briggs JP. Persistence of circadian variation in arterial blood pressure in beta1/beta2- adrenergic receptor-deficient mice. Am J Physiol Regul Integr Comp Physiol. 2008;294:R1427-R1434.